ROCK inhibitor Bravyl may reduce spread of TDP-43 clumps in ALS
Bravyl (oral fasudil), an experimental therapy Woolsey Pharmaceuticals is developing for amyotrophic lateral sclerosis (ALS), significantly reduced the…
Articles by Andrea Lobo, PhD
Kadimastem, NLS merge to advance ALS therapy AstroRx, other drugs
Kadimastem, the developer of the experimental amyotrophic lateral sclerosis (ALS) therapy AstroRx, is merging with NLS Pharmaceutics…
Woolsey gets 3 US patents covering ROCK inhibitor Bravyl
Woolsey Pharmaceuticals has received three new U.S. patents covering innovations related to Bravyl (oral fasudil), its investigational amyotrophic lateral…
Texas Children’s investigator wins $2.4M grant for ALS research
A Texas Children’s Hospital investigator has received a $2.4 million grant for a study that seeks to understand whether mechanisms…
Avextra to launch Phase 2 trial of cannabis-based medicine in Italy
Avextra is set to launch a Phase 2 trial in Italy to test a cannabis-based oral medication for the…
PrimeC, potential ALS treatment, given US patent for its formulation
Neurosense Therapeutics announced that it has received a U.S. patent covering the formulation of PrimeC, its…
Mabylon gets funding to advance human-derived antibodies for ALS
The Swiss biotechnology company Mabylon has received two research grants from Target ALS and the ALS Association…
Clene granted in-person FDA meeting on CNM-Au8 for ALS
Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held…
Amprion wins $100K to study causes of sporadic ALS
Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral…
AcuraStem receives $4M grant to advance ASO treatment for ALS
AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development…